Cargando…
Risk factor reduction in progression of angiographic coronary artery disease
INTRODUCTION: To investigate differences between outpatients with progressive and nonprogressive coronary artery disease (CAD) measured by coronary angiography. MATERIAL AND METHODS: Chart reviews were performed in patients in an outpatient cardiology practice having ≥ 2 coronary angiographies ≥ 1 y...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400910/ https://www.ncbi.nlm.nih.gov/pubmed/22851998 http://dx.doi.org/10.5114/aoms.2012.29399 |
_version_ | 1782238545360977920 |
---|---|
author | Lai, Hoang M. Aronow, Wilbert S. Mercando, Anthony D. Kalen, Phoenix Desai, Harit V. Gandhi, Kaushang Sharma, Mala Amin, Harshad Lai, Trung M. |
author_facet | Lai, Hoang M. Aronow, Wilbert S. Mercando, Anthony D. Kalen, Phoenix Desai, Harit V. Gandhi, Kaushang Sharma, Mala Amin, Harshad Lai, Trung M. |
author_sort | Lai, Hoang M. |
collection | PubMed |
description | INTRODUCTION: To investigate differences between outpatients with progressive and nonprogressive coronary artery disease (CAD) measured by coronary angiography. MATERIAL AND METHODS: Chart reviews were performed in patients in an outpatient cardiology practice having ≥ 2 coronary angiographies ≥ 1 year apart. Progressive CAD was defined as 1) new non-obstructive or obstructive CAD in a previously disease-free vessel; or 2) new obstruction in a previously non-obstructive vessel. Coronary risk factors, comorbidities, cardiovascular events, medication use, serum low-density lipoprotein cholesterol (LDL-C), and blood pressure were used for analysis. RESULTS: The study included 183 patients, mean age 71 years. Mean follow-up duration was 11 years. Mean follow-up between coronary angiographies was 58 months. Of 183 patients, 108 (59%) had progressive CAD, and 75 (41%) had nonprogressive CAD. The use of statins, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aspirin was not significantly different in patient with progressive CAD or nonprogressive CAD Mean arterial pressure was higher in patients with progressive CAD than in patients with nonprogressive CAD (97±13 mm Hg vs. 92±12 mm Hg) (p<0.05). Serum LDL-C was insignificantly higher in patients with progressive CAD (94±40 mg/dl) than in patients with nonprogressive CAD (81±34 mg/dl) (p=0.09). CONCLUSIONS: Our data suggest that in addition to using appropriate medical therapy, control of blood pressure and serum LDL-C level may reduce progression of CAD. |
format | Online Article Text |
id | pubmed-3400910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-34009102012-07-31 Risk factor reduction in progression of angiographic coronary artery disease Lai, Hoang M. Aronow, Wilbert S. Mercando, Anthony D. Kalen, Phoenix Desai, Harit V. Gandhi, Kaushang Sharma, Mala Amin, Harshad Lai, Trung M. Arch Med Sci Clinical Research INTRODUCTION: To investigate differences between outpatients with progressive and nonprogressive coronary artery disease (CAD) measured by coronary angiography. MATERIAL AND METHODS: Chart reviews were performed in patients in an outpatient cardiology practice having ≥ 2 coronary angiographies ≥ 1 year apart. Progressive CAD was defined as 1) new non-obstructive or obstructive CAD in a previously disease-free vessel; or 2) new obstruction in a previously non-obstructive vessel. Coronary risk factors, comorbidities, cardiovascular events, medication use, serum low-density lipoprotein cholesterol (LDL-C), and blood pressure were used for analysis. RESULTS: The study included 183 patients, mean age 71 years. Mean follow-up duration was 11 years. Mean follow-up between coronary angiographies was 58 months. Of 183 patients, 108 (59%) had progressive CAD, and 75 (41%) had nonprogressive CAD. The use of statins, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aspirin was not significantly different in patient with progressive CAD or nonprogressive CAD Mean arterial pressure was higher in patients with progressive CAD than in patients with nonprogressive CAD (97±13 mm Hg vs. 92±12 mm Hg) (p<0.05). Serum LDL-C was insignificantly higher in patients with progressive CAD (94±40 mg/dl) than in patients with nonprogressive CAD (81±34 mg/dl) (p=0.09). CONCLUSIONS: Our data suggest that in addition to using appropriate medical therapy, control of blood pressure and serum LDL-C level may reduce progression of CAD. Termedia Publishing House 2012-07-04 2012-07-04 /pmc/articles/PMC3400910/ /pubmed/22851998 http://dx.doi.org/10.5114/aoms.2012.29399 Text en Copyright © 2012 Termedia & Banach http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Research Lai, Hoang M. Aronow, Wilbert S. Mercando, Anthony D. Kalen, Phoenix Desai, Harit V. Gandhi, Kaushang Sharma, Mala Amin, Harshad Lai, Trung M. Risk factor reduction in progression of angiographic coronary artery disease |
title | Risk factor reduction in progression of angiographic coronary artery disease |
title_full | Risk factor reduction in progression of angiographic coronary artery disease |
title_fullStr | Risk factor reduction in progression of angiographic coronary artery disease |
title_full_unstemmed | Risk factor reduction in progression of angiographic coronary artery disease |
title_short | Risk factor reduction in progression of angiographic coronary artery disease |
title_sort | risk factor reduction in progression of angiographic coronary artery disease |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400910/ https://www.ncbi.nlm.nih.gov/pubmed/22851998 http://dx.doi.org/10.5114/aoms.2012.29399 |
work_keys_str_mv | AT laihoangm riskfactorreductioninprogressionofangiographiccoronaryarterydisease AT aronowwilberts riskfactorreductioninprogressionofangiographiccoronaryarterydisease AT mercandoanthonyd riskfactorreductioninprogressionofangiographiccoronaryarterydisease AT kalenphoenix riskfactorreductioninprogressionofangiographiccoronaryarterydisease AT desaiharitv riskfactorreductioninprogressionofangiographiccoronaryarterydisease AT gandhikaushang riskfactorreductioninprogressionofangiographiccoronaryarterydisease AT sharmamala riskfactorreductioninprogressionofangiographiccoronaryarterydisease AT aminharshad riskfactorreductioninprogressionofangiographiccoronaryarterydisease AT laitrungm riskfactorreductioninprogressionofangiographiccoronaryarterydisease |